Idera Pharmaceuticals Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Idera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IDRA, but not buy additional shares or sell existing shares.
View analyst ratings for Idera Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Idera Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Idera Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Idera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Idera Pharmaceuticals.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced its quarterly earnings results on Thursday, April, 29th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.08.
View Idera Pharmaceuticals' earnings history.

Idera Pharmaceuticals' stock was trading at $1.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IDRA stock has decreased by 5.1% and is now trading at $1.31.
View which stocks have been most impacted by COVID-19.

Shares of Idera Pharmaceuticals reverse split before market open on Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

5 brokerages have issued 1-year target prices for Idera Pharmaceuticals' stock. Their forecasts range from $1.00 to $9.00. On average, they expect Idera Pharmaceuticals' share price to reach $4.00 in the next year. This suggests a possible upside of 205.3% from the stock's current price.
View analysts' price targets for Idera Pharmaceuticals or view top-rated stocks among Wall Street analysts.

7 employees have rated Idera Pharmaceuticals CEO Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among Idera Pharmaceuticals' employees.

Some companies that are related to Idera Pharmaceuticals include CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA), Immatics (IMTX), Cabaletta Bio (CABA), X4 Pharmaceuticals (XFOR), Genfit (GNFT), Axcella Health (AXLA), Applied Genetic Technologies (AGTC), Voyager Therapeutics (VYGR), Fennec Pharmaceuticals (FENC), Gamida Cell (GMDA), Xtant Medical (XTNT), Checkmate Pharmaceuticals (CMPI), LogicBio Therapeutics (LOGC) and Ayala Pharmaceuticals (AYLA).
View all of IDRA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include (OAS), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Dynavax Technologies (DVAX), Proteostasis Therapeutics (PTI), Geron (GERN), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO) and Anavex Life Sciences (AVXL).

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Idera Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (4.09%), BlackRock Inc. (1.27%), Geode Capital Management LLC (0.52%), Acadian Asset Management LLC (0.43%), Virtu Financial LLC (0.29%) and Hollencrest Capital Management (0.33%). Company insiders that own Idera Pharmaceuticals stock include Bryant David Lim, Daniel B Soland, Elizabeth Ann Tarka, Invest Corp Pillar, John J Kirby, Jonathan Michael Yingling, Robert C Fletcher and Vincent Milano.
View institutional ownership trends for Idera Pharmaceuticals.

IDRA stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, and Renaissance Technologies LLC. Company insiders that have sold Idera Pharmaceuticals company stock in the last year include Bryant David Lim, Elizabeth Ann Tarka, John J Kirby, and Vincent Milano.
View insider buying and selling activity for Idera Pharmaceuticals or view top insider-selling stocks.

IDRA stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Virtu Financial LLC, Morgan Stanley, Geode Capital Management LLC, HRT Financial LP, Hollencrest Capital Management, Wade G W & Inc., and Advisory Services Network LLC. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Daniel B Soland, and Invest Corp Pillar.
View insider buying and selling activity for Idera Pharmaceuticals or or view top insider-buying stocks.

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDRA stock can currently be purchased for approximately $1.31.

Idera Pharmaceuticals has a market capitalization of $65.54 million and generates $1.45 million in revenue each year. The biotechnology company earns $-112,660,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.

Idera Pharmaceuticals employs 32 workers across the globe.

Idera Pharmaceuticals was founded in 1989.

The official website for Idera Pharmaceuticals is www.iderapharma.com.

Idera Pharmaceuticals is headquartered at 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341.

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected]